Lamstatin - a novel inhibitor of lymphangiogenesis derived from collagen IV

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 12, 2012, Pages 3062-3073

  Weckmann, Markus ^a,b,c,e   Moir, Lyn Margaret ^a,b,c   Heckman, Caroline Akemi ^d   Black, Judith Lee ^a,b,c   Oliver, Brian Gregory ^a,b,c   Burgess, Janette Kay ^a,b,c  

^a WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b Cooperative Research Centre for Asthma and Airways ^*  (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Collagen; Lymphangiogenesis; Lymphangioleiomyomatosis; Type IV collagen alpha5 chain

Indexed keywords

ANGIOGENESIS INHIBITOR; COLLAGEN TYPE 4; LAMSTATIN; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; ENDOTHELIUM CELL; HUMAN; LYMPH VESSEL; LYMPHANGIOGENESIS; LYMPHANGIOLEIOMYOMATOSIS; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; PROTEIN TERTIARY STRUCTURE; SCID MOUSE; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN TYPE IV; ENDOTHELIAL CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LYMPHANGIOGENESIS; LYMPHANGIOLEIOMYOMATOSIS; LYMPHATIC VESSELS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; ESCHERICHIA COLI;

EID: 84871059512     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01648.x     Document Type: Article

References (58)

1. Albrecht I, Christofori G. Molecular mechanisms of lymphangiogenesis in development and cancer. Int J Dev Biol. 2011; 55: 483-94.
2. Chang LK, Garcia-Cardena G, Farnebo F, et al. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A. 2004; 101: 11658-63.
3. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996; 87: 1161-9.
4. Kubo H, Cao R, Brakenhielm E, et al. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Nat Acad Sci USA. 2002; 99: 8868-73.
5. Shin JW, Min M, Larrieu-Lahargue F, et al. Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. Mol Biol Cell. 2006; 17: 576-84.
6. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Nat Acad Sci USA. 1998; 95: 548-53.
7. Dumont DJ, Jussila L, Taipale J, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science. 1998; 282: 946-9.
8. Joukov V, Sorsa T, Kumar V, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 1997; 16: 3898-911.
9. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Nat Acad Sci USA. 1995; 92: 3566-70.
10. Partanen TA, Arola J, Saaristo A, et al. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J. 2000; 14: 2087-96.
11. Burgess JK, Boustany S, Moir LM, et al. Reduction of tumstatin in asthmatic airways contributes to angiogenesis, inflammation, and hyperresponsiveness. Am J Respir Crit Care Med. 2010; 181: 106-15.
12. Dehan P, Waltregny D, Beschin A, et al. Loss of type IV collagen alpha 5 and alpha 6 chains in human invasive prostate carcinomas. Am J Pathol. 1997; 151: 1097-104.
13. Ikeda K, Iyama K, Ishikawa N, et al. Loss of expression of type IV collagen alpha5 and alpha6 chains in colorectal cancer associated with the hypermethylation of their promoter region. Am J Pathol. 2006; 168: 856-65.
14. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat. 2005; 91: 125-32.
15. Nakano KY, Iyama KI, Mori T, et al. Loss of alveolar basement membrane type IV collagen alpha3, alpha4, and alpha5 chains in bronchioloalveolar carcinoma of the lung. J Pathol. 2001; 194: 420-7.
16. Ninomiya Y, Kagawa M, Iyama K, et al. Differential expression of two basement membrane collagen genes, COL4A6 and COL4A5, demonstrated by immunofluorescence staining using peptide-specific monoclonal antibodies. J Cell Biol. 1995; 130: 1219-29.
17. Karagiannis ED, Popel AS. A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc Nat Acad Sci USA. 2008; 105: 13775-80.
18. Ortega N, Werb Z. New functional roles for non-collagenous domains of basement membrane collagens. J Cell Sci. 2002; 115: 4201-14.
19. Hohman DW, Noghrehkar D, Ratnayake S. Lymphangioleiomyomatosis: A review. Eur J Intern Med. 2008; 19: 319-24.
20. Henske EP. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosom Cancer. 2003; 38: 376-81.
21. Pacheco-Rodriguez G, Kumaki F, Steagall WK, et al. Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene. J Immunol. 2009; 182: 1270-7.
22. Pitts S, Oberstein EM, Glassberg MK. Benign metastasizing leiomyoma and lymphangioleiomyomatosis: sex-specific diseases? Clin Chest Med. 2004; 25: 343-60.
23. Yu J, Henske EP. mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis. Lymphat Res Biol. 2010; 8: 43-9.
24. Black JL, Ge Q, Boustany S, et al. In vitro studies of lymphangioleiomyomatosis. Eur Res J. 2005; 26: 569-76.
25. Goncharova EA, Goncharov DA, Spaits M, et al. Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2. Am J Respir Cell Mol Biol. 2006; 34: 561-72.
26. Merrilees MJ, Hankin EJ, Black JL, et al. Matrix proteoglycans and remodelling of interstitial lung tissue in lymphangioleiomyomatosis. J Pathol. 2004; 203: 653-60.
27. Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol. 2004; 28: 1007-16.
28. Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol. 2006; 4: 143-52.
29. Inoue Y, King TE, Barker E, et al. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2002; 166: 765-73.
30. Moir LM, Trian T, Ge Q, et al. PI 3-Kinase isoform specific effects in airway mesenchymal cell function. J Pharmacol Exp Ther. 2011; 337: 557-66
31. Burgess JK, Carlin S, Pack RA, et al. Detection and characterization of OX40 ligand expression in human airway smooth muscle cells: a possible role in asthma? J Allergy Clin Immunol. 2004; 113: 683-9.
32. Burgess JK, Ge Q, Boustany S, et al. Increased sensitivity of asthmatic airway smooth muscle cells to prostaglandin E2 might be mediated by increased numbers of E-prostanoid receptors. J Allergy Clin Immunol. 2004; 113: 876-81.
33. Burgess JK, Oliver BGG, Poniris MH, et al. A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro. J Allergy Clin Immunol. 2006; 118: 649-57.
34. Hostettler KE, Roth M, Burgess JK, et al. Cyclosporine A mediates fibroproliferation through epithelial cells. Transplantation. 2004; 77: 1886-93.
35. Johnson PR, Black JL, Carlin S, et al. The production of extracellular matrix proteins by human passively sensitized airway smooth-muscle cells in culture: the effect of beclomethasone. Am J Respir Crit Care Med. 2000; 162: 2145-51.
36. Johnson PRA, Roth M, Tamm M, et al. Airway smooth muscle cell proliferation is increased in asthma. Am J Respir Crit Care Med. 2001; 164: 474-7.
37. Moir L, Ng H, Poniris M, et al. Doxycycline inhibits matrix metalloproteinase-2 secretion from TSC2-null mouse embryonic fibroblasts and lymphangioleiomyomatosis cells. Br J Pharmacol. 2011; 164: 83-92
38. Maeshima Y, Manfredi M, Reimer C, et al. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem. 2001; 276: 15240-8.
39. Maeshima Y, Yerramalla UL, Dhanabal M, et al. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. J Biol Chem. 2001; 276: 31959-68.
40. Heckman CA, Holopainen T, Wirzenius M, et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 2008; 68: 4754-62.
41. Shayan R, Karnezis T, Tsantikos E, et al. A system for quantifying the patterning of the lymphatic vasculature. Growth Factors. 2007; 25: 417-25.
42. Albuquerque RJ, Hayashi T, Cho WG, et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med. 2009; 15: 1023-30.
43. Kinet V, Castermans K, Herkenne S, et al. The angiostatic protein 16K human prolactin significantly prevents tumor-induced lymphangiogenesis by affecting lymphatic endothelial cells. Endocrinology. 2011; 152: 4062-71.
44. Hwang-Bo J, Yoo KH, Park JH, et al. Recombinant canstatin inhibits angiopoietin-1-induced angiogenesis and lymphangiogenesis. Int J Cancer. 2012; 131: 298-309.
45. Shao XJ, Xie FM. Influence of angiogenesis inhibitors, endostatin and PF-4, on lymphangiogenesis. Lymphology. 2005; 38: 1-8.
46. Dong X, Zhao X, Xiao T, et al. Endostar, a recombined humanized endostatin, inhibits lymphangiogenesis and lymphatic metastasis of Lewis lung carcinoma xenograft in mice. Thorac Cardiovasc Surg. 2011; 59: 133-6.
47. Brideau G, Makinen MJ, Elamaa H, et al. Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res. 2007; 67: 11528-35.
48. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000; 156: 1363-80.
49. Dudley AC. Tumor endothelial cells. Cold Spring Harb Perspect Med. 2012; 2: a006536.
50. Hiki Y, Iyama K, Tsuruta J, et al. Differential distribution of basement membrane type IV collagen alpha1(IV), alpha2(IV), alpha5(IV) and alpha6(IV) chains in colorectal epithelial tumors. Pathol Int. 2002; 52: 224-33.
51. Hinenoya N, Naito I, Momota R, et al. Type IV collagen alpha chains of the basement membrane in the rat bronchioalveolar transitional segment. Arch Histol Cytol. 2008; 71: 185-94.
52. Nakano S, Iyama K, Ogawa M, et al. Differential tissular expression and localization of type IV collagen alpha1(IV), alpha2(IV), alpha5(IV), and alpha6(IV) chains and their mRNA in normal breast and in benign and malignant breast tumors. Lab Invest. 1999; 79: 281-92.
53. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001; 7: 192-8.
54. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001; 7: 186-91.
55. Yano A, Fujii Y, Iwai A, et al. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res. 2006; 12: 6012-7.
56. Zeng Y, Opeskin K, Horvath LG, et al. Lymphatic vessel density and lymph node metastasis in prostate cancer. Prostate. 2005; 65: 222-30.
57. Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol. 2005; 29: 1356-66.
58. Hirama M, Atsuta R, Mitani K, et al. Lymphangioleiomyomatosis diagnosed by immunocytochemical and genetic analysis of lymphangioleiomyomatosis cell clusters found in chylous pleural effusion. Intern Med. 2007; 46: 1593-6.